RAC1 and ovarian cancer: In ovarian cancer, Gonzalez-Villasana et al. demonstrate the ability of zoledronic acid to inhibit RAC1 activity and suppress a larger RAC1/PAK1/MMP-2 signaling pathway and ultimate pro-angiogenic phenotype [57].